Coexistence of primary aldosteronism and Hashimoto’s thyroiditis by Robert Krysiak & Bogusław Okopien
Rheumatol Int (2012) 32:2561–2563
DOI 10.1007/s00296-011-2032-6
SHORT COMMUNICATION
Coexistence of primary aldosteronism and Hashimoto’s 
thyroiditis
Robert Krysiak · Bogusiaw Okopien 
Received: 7 February 2011 / Accepted: 10 July 2011 / Published online: 26 July 2011
© The Author(s) 2011
Abstract In light of research carried out in recent years, it
seems that aldosterone may produce a complex proinXam-
matory eVect. Theoretically, excessive aldosterone release
may stimulate the development and/or progression of auto-
immune disorders. In this article, we report a case of a
female in whom primary aldosteronism coexisted with
Hashimoto’s thyroiditis. Surgical removal of an aldoste-
rone-producing tumor improved thyroid function and
decreased thyroid autoimmunity. We describe in details
diagnostic and treatment strategies applied in our patient
and their impact on the course and outcome of thyroiditis.
We also present monocyte and lymphocyte cytokine release
in the index subjects before and after surgical treatment.
We conclude that primary aldosteronism may exacerbate
the clinical course of autoimmune thyroiditis and probably
also of other autoimmune disorders.
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Introduction
Primary aldosteronism is one of the leading causes of sec-
ondary hypertension, particularly in women. It may be
responsible for as much as 5–13% of all cases of arterial
hypertension and about 20% cases of treatment-resistant
hypertension [1, 2]. The pathophysiological role of aldoste-
rone in cardiovascular disorders is mediated not only by its
hypertensive eVect but also by its proinXammatory action
through the mineralocorticoid receptor in non-epithelial
cells [3]. Chronic lymphocytic thyroiditis, often referred to
as Hashimoto’s thyroiditis, belongs to the most common
human disorders, particularly in women, with the incidence
estimated at 3.5 cases per 1,000 women per year [4, 5]. As
in other autoimmune disorders, Hashimoto’s thyroiditis is
characterized by a lymphocytic inWltration of the thyroid
and the presence of speciWc antibodies [4, 5]. Interestingly,
only one previous study assessed the coincidence of the two
disorders in the same patient [6]. In our article, we report
that primary aldosteronism may aVect the course of chronic
thyroiditis.
Case report
A 36-year-old woman was admitted to our hospital to deter-
mine the reasons for arterial hypertension she had suVered
for 6 years and which was resistant to standard antihyper-
tensive therapy. Hypertension was accompanied by muscle
weakness, acral paresthesias, polyuria and polydipsia,
observed irrespective of the time of the day. In view of
signiWcant hypokalemia (2.8 mmol/l) with kaliuresis
112 mEq/l (reference range: 25–100 mmol/l) and hyperglyce-
mia (6.8 mmol/l), primary aldosteronism was suspected and
investigated. Supine plasma renin activity was 0.02 ng/ml/h,
(reference range: 0.3–2.8 ng/ml/h), while supine plasma aldo-
sterone was 648 pg/ml (normal values: 30–150 pg/ml).
After standing for 4 h, plasma renin activity and plasma
aldosterone levels increased only slightly to 0.03 ng/ml/h
and 687 ng/dl, respectively. Provocative tests, the saline
infusion test (2 l during 4 h) and the Xudrocortisone with
salt loading test revealed unsuppressed plasma aldosterone
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2562 Rheumatol Int (2012) 32:2561–2563levels (389 and 426 ng/dl, respectively; normal values in
both these tests <5.0 ng/dl). Computed tomography exami-
nation demonstrated a minimally enhancing hypodense
mass (16 mm in diameter) in the left adrenal gland. A 1 mg
dexamethasone suppression test signiWcantly decreased
plasma cortisol levels (to 0.6 g/dl). Urinary-free cortisol,
plasma dehydroepiandrosterone sulfate as well as diurnal
urinary excretion of metanephrines were also normal.
Because of contraindications (allergy to contrast dye), bilat-
eral adrenal vein sampling was not performed. Owing to
the presence of concomitant weight gain, depressive symp-
toms and cold intolerance, we also investigated thyroid
function and autoimmunity. Increased plasma TSH levels
(23.2 mIU/l, reference range: 0.4–4.5) and reduced plasma
levels of free thyroxine (8.8 pmol/l, reference range: 12.0–
22.0) and free triiodothyronine (2.6 pmol/l, reference
range: 2.8–6.0) supported the presence of hypothyroidism.
In turn, very high titers of both thyroid peroxidase antibod-
ies (3,200 U/ml, normal values <32) and thyroglobulin
antibodies (3,400 U/ml, normal values <100), diVused thy-
roid hypoechogenecity on sonography as well as extensive
lymphocytic inWltration and numerous Askanazy cells on
Wne needle aspiration biopsy all were compatible with
Hashimoto’s thyroiditis. Cultures of human peripheral
blood monocytes and lymphocytes,1 performed as
described previously [7, 8], showed increased monocyte
release of TNF- (3,870 pg/ml, reference range: 580–860),
interleukin-1 (440 pg/ml, reference range: 51–79), inter-
leukin-6 (30.2 ng/ml, reference range: 4.3–8.7) and mono-
cyte chemoattractant protein (36.4 ng/ml, reference range:
10.1–14.5), as well as increased lymphocyte release of
TNF- (810 pg/ml reference range: 145–225), interferon-
(180 ng/ml reference range: 21–45) and interleukin-2
(10.1 ng/ml reference range: 1,4–4.4). To normalize thyroid
function, the patient required levothyroxine supplementa-
tion at the daily dose of 125 g. Three months later after
pretreatment with spironolactone, the patient underwent
laparoscopic left adrenalectomy. Interestingly, after the fol-
lowing 4 months, the patient noticed weight loss despite
increased appetite, hyperactivity, heat intolerance, irritabil-
ity and tachycardia. TSH levels were found suppressed
(0.002 mU/l), while free thyroxine and free triiodothyro-
nine were found increased (24.2 and 7.4 pmol/l, respec-
tively). Thyroid peroxidase antibodies and thyroglobulin
antibodies (345 and 420 U/ml) were only moderately ele-
vated, and thyroid hypoechogenecity was much less
expressed than seven months earlier. Only after reducing
the daily dose of levothyroxine to 50 g, all his clinical
symptoms resolved and thyroid function returned to nor-
mal. Post-surgery monocyte release of TNF- (1,020 pg/
ml), interleukin-1 (89 pg/ml), interleukin-6 (9.8 ng/ml)
and monocyte chemoattractant protein (16.1 ng/ml) as well
as lymphocyte release of TNF- (285 pg/ml), interferon-
(59 ng/ml) and interleukin-2 (5.1 ng/ml) was only slightly
elevated and much lower than observed after spironolactone
pretreatment (monocyte release of TNF-—2,780 pg/ml, inter-
leukin-1—245 pg/ml, interleukin-6–28.3 ng/ml and mono-
cyte chemoattractant protein—27.2 ng/ml; lymphocyte
release of TNF-—630 pg/ml, interferon-—172 ng/ml and
interleukin-2–8.8 ng/ml).
Discussion
In this paper, we report for the Wrst time that primary aldo-
steronism may exacerbate the course of autoimmune thy-
roid disease. Taking into account that both primary
aldosteronism and Hashimoto’s thyroiditis are common
disorders in the general population, it cannot be excluded
that their coincidence in the same patient was only acciden-
tal. However, it is as well possible that excessive aldoste-
rone release may lead to the development of thyroid
inWltration by inXammatory cells in predisposed individu-
als. Even if there are controversies concerning the relation-
ship between high aldosterone and the development of
thyroiditis in the index subjects, there are no doubts that
primary aldosteronism exacerbated the clinical course of
chronic thyroiditis.
Taking into account the pattern of cytokine release
(tumor necrosis factor-, interleukin-2, interferon-),
chronic thyroiditis is classiWed as a Th1 disorder [9]. In our
patient, both monocyte and lymphocyte release of proin-
Xammatory cytokines were more pronounced in the time
when thyroiditis coexisted with an aldosterone-producing
adrenal tumor than after spironolactone pretreatment and
after surgery. Our Wnding is in line with the results by
Bendtzen et al. [10], who observed that spironolactone
reduced tumor necrosis factor- and interferon- produc-
tion in patients with rheumatoid and juvenile idiopathic
arthritis. Therefore, our results show that surgical removal
of the tumor may inhibit the cell-mediated immune
response in the similar way as spironolactone does. This
eVect seems, however, to be stronger than that of spirono-
lactone because post-surgery cytokine release in the index
subject was reduced when compared with that after spiro-
nolactone pretreatment and only slightly higher than
observed in healthy population.
Although our patient suVered from chronic thyroiditis,
similar relationships may exist between primary aldoste-
ronism and other coexisting autoimmune disorders. It
seems that such patients may beneWt more from surgical
than pharmacological treatment of primary aldosteronism.
Fortunately, as our case shows, if treated, the proinXammatory
1 Blood samples were collected when blood pressure was within nor-
mal limits (the patient was treated with verapamil and prazosin).123
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some degree, reversible.
To sum up, primary aldosteronism may exacerbate the
clinical course of autoimmune thyroiditis and probably also
other autoimmune disorders. Therefore, patients with resis-
tant arterial hypertension coexisting with autoimmune dis-
orders should be assessed for the presence of primary
aldosteronism.
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